文献速递肝病消化道肿瘤与早癌

慢性乙型肝炎基线病毒载量与治疗中肝细胞癌风险:一项多国队列研究

Baseline Viral Load and On-Treatment Hepatocellular Carcinoma Risk in Chronic Hepatitis B: A Multinational Cohort Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-08-23

这项多国队列研究纳入20,826例无肝硬化、HBeAg阳性或阴性且基线HBV DNA≥2000 IU/mL、起始恩替卡韦或替诺福韦治疗的慢性乙型肝炎患者,中位随访4.1年期间663例发生肝细胞癌,发生率0.81/100人年(95%CI 0.75-0.87)。基线病毒载量与治疗中肝细胞癌风险呈显著非线性抛物线关联,基线6.00-7.00 log10 IU/mL组风险最高(校正HR 4.28,95%CI 2.15-8.52,P<.0001),≥8.00 log10 IU/mL组风险最低。

要点

  • 基线HBV DNA与治疗中肝细胞癌风险呈非线性抛物线关联。
  • 基线6.00-7.00 log10 IU/mL组肝细胞癌风险最高,校正HR 4.28。
  • 基线≥8.00 log10 IU/mL组肝细胞癌风险最低。

核心结论

  • 在无肝硬化的慢性乙型肝炎患者中,基线病毒载量与抗病毒治疗期间肝细胞癌风险呈显著非线性抛物线关联。
  • 基于HBV病毒载量早期启动抗病毒治疗可能有助于预防慢性乙型肝炎患者不可逆的肝细胞癌风险累积。

研究设计与样本

  • 多国队列研究,纳入20,826例无肝硬化、HBeAg阳性或HBeAg阴性且基线HBV DNA≥2000 IU/mL(3.30 log10 IU/mL)的慢性乙型肝炎患者,均起始恩替卡韦或替诺福韦治疗。
  • 主要结局为治疗中肝细胞癌发生率,按基线HBV病毒载量分类变量分层分析。

主要发现

  • 中位随访4.1年期间共663例发生肝细胞癌,发生率为0.81/100人年(95%CI 0.75-0.87)。
  • 基线HBV病毒载量与肝细胞癌风险呈显著非线性抛物线关联,且独立于其他因素。
  • 与基线病毒载量≥8.00 log10 IU/mL组相比,基线6.00-7.00 log10 IU/mL组治疗中肝细胞癌风险最高(校正HR 4.28,95%CI 2.15-8.52,P<.0001),后者风险最低。

临床怎么用

  • 作者认为,基于HBV病毒载量早期启动抗病毒治疗可能有助于预防慢性乙型肝炎患者不可逆的肝细胞癌风险累积。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) risk persists in patients with chronic hepatitis B (CHB) despite antiviral therapy. The relationship between pre-treatment baseline hepatitis B virus (HBV) viral load and HCC risk during antiviral treatment remains uncertain. METHODS: This multinational cohort study aimed to investigate the association between baseline HBV viral load and on-treatment HCC risk in 20,826 noncirrhotic, hepatitis B e antigen (HBeAg)-positive and HBeAg-negative patients with baseline HBV DNA levels ≥2000 IU/mL (3.30 log10 IU/mL) who initiated entecavir or tenofovir treatment. The primary outcome was on-treatment HCC incidence, stratified by baseline HBV viral load as a categorical variable. RESULTS: In total, 663 patients developed HCC over a median follow-up of 4.1 years, with an incidence rate of 0.81 per 100 person-years (95% confidence interval [CI], 0.75-0.87). Baseline HBV viral load was significantly associated with HCC risk in a non-linear parabolic pattern, independent of other factors. Patients with baseline viral load between 6.00 and 7.00 log10 IU/mL had the highest on-treatment HCC risk (adjusted hazard ratio, 4.28; 95% CI, 2.15-8.52; P < .0001) compared with those with baseline viral load ≥8.00 log10 IU/mL, who exhibited the lowest HCC risk. CONCLUSION: Baseline viral load showed a significant, non-linear, parabolic association with HCC risk during antiviral treatment in noncirrhotic patients with CHB. Early initiation of antiviral treatment based on HBV viral load may help prevent irreversible HCC risk accumulation in patients with CHB.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Choi WM, Yip TC, Wong GL, et al. Baseline Viral Load and On-Treatment Hepatocellular Carcinoma Risk in Chronic Hepatitis B: A Multinational Cohort Study. Clin Gastroenterol Hepatol. 2024. PMID: 39181430. doi:10.1016/j.cgh.2024.07.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。